James E. Chastain

457 total citations
17 papers, 309 citations indexed

About

James E. Chastain is a scholar working on Ophthalmology, Molecular Biology and Oncology. According to data from OpenAlex, James E. Chastain has authored 17 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Ophthalmology, 4 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in James E. Chastain's work include Glaucoma and retinal disorders (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Retinal Diseases and Treatments (3 papers). James E. Chastain is often cited by papers focused on Glaucoma and retinal disorders (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and Retinal Diseases and Treatments (3 papers). James E. Chastain collaborates with scholars based in United States, Switzerland and United Kingdom. James E. Chastain's co-authors include Uday B. Kompella, Chandrasekar Durairaj, Thomas L. Pazdernik, Mark Sanders, David C. Dahlin, Michael A. Curtis, Patricia Heacock, Elaine Souder, Nagendra Chemuturi and Martha E. Gadd and has published in prestigious journals such as Neuroscience, Life Sciences and European Journal of Pharmacology.

In The Last Decade

James E. Chastain

17 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Chastain United States	11	135	94	92	42	24	17	309
Maria D. Donovan Ireland	11	50 0.4×	218 2.3×	22 0.2×	14 0.3×	39 1.6×	21	480
Lisa Cheeks United States	13	240 1.8×	68 0.7×	156 1.7×	110 2.6×	2 0.1×	41	427
Tadahiro Murakami Japan	11	211 1.6×	30 0.3×	189 2.1×	415 9.9×	30 1.3×	24	559
Sonja Krösser United States	16	208 1.5×	60 0.6×	233 2.5×	452 10.8×	8 0.3×	31	624
Shan Duan China	9	143 1.1×	211 2.2×	51 0.6×	9 0.2×	15 0.6×	42	416
Nan Yan China	12	46 0.3×	141 1.5×	23 0.3×	3 0.1×	30 1.3×	56	419
A. A. Voskresenskaya Russia	10	103 0.8×	160 1.7×	109 1.2×	23 0.5×	7 0.3×	25	316
Jess T. Whitson United States	21	866 6.4×	139 1.5×	426 4.6×	353 8.4×	6 0.3×	41	1.0k
Hien Thi Vu Australia	10	169 1.3×	128 1.4×	110 1.2×	21 0.5×	3 0.1×	13	457
Teresia A. Carreon United States	7	264 2.0×	99 1.1×	144 1.6×	58 1.4×	4 0.2×	8	414

Countries citing papers authored by James E. Chastain

Since Specialization

Citations

This map shows the geographic impact of James E. Chastain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Chastain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Chastain more than expected).

Fields of papers citing papers by James E. Chastain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Chastain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Chastain. The network helps show where James E. Chastain may publish in the future.

Co-authorship network of co-authors of James E. Chastain

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Chastain. A scholar is included among the top collaborators of James E. Chastain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Chastain. James E. Chastain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Mogi, Muneto, Anisha E. Mendonza, James E. Chastain, et al.. (2023). Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep). Translational Vision Science & Technology. 12(9). 5–5. 7 indexed citations

Poor, Stephen, Georges Weissgerber, Christopher M. Adams, et al.. (2022). A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology. 239. 180–189. 13 indexed citations

Yang, Junzheng, John Demirs, Julien P. N. Papillon, et al.. (2021). In-vitro and In-vivo pharmacology of SAF312 as a TRPV1 inhibitor for ocular surface pain. 62(8). 722–722. 2 indexed citations

Fleck, Brian W., Andreas Stahl, Neil Marlow, et al.. (2020). Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial. Translational Vision Science & Technology. 9(8). 43–43. 31 indexed citations

Chemuturi, Nagendra, Mark Milton, Gian Camenisch, et al.. (2018). Models and Approaches Describing the Metabolism, Transport, and Toxicity of Drugs Administered by the Ocular Route. Drug Metabolism and Disposition. 46(11). 1670–1683. 14 indexed citations

Yáñez, Jaime A., et al.. (2016). Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates. Investigative Ophthalmology & Visual Science. 57(12). 4996–4996. 13 indexed citations

Li, Guangming, et al.. (2015). Ocular Pharmacokinetics Comparison Between 0.2% Olopatadine and 0.77% Olopatadine Hydrochloride Ophthalmic Solutions Administered to Male New Zealand White Rabbits. Journal of Ocular Pharmacology and Therapeutics. 31(4). 204–210. 14 indexed citations

Chastain, James E., Mark Sanders, Michael A. Curtis, et al.. (2015). Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Experimental Eye Research. 145. 58–67. 36 indexed citations

Durairaj, Chandrasekar, James E. Chastain, & Uday B. Kompella. (2012). Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Experimental Eye Research. 98. 23–27. 64 indexed citations

10.

Missel, Paul J., James E. Chastain, Ashim K. Mitra, et al.. (2010). In Vitro Transport and Partitioning of AL-4940, Active Metabolite of Angiostatic Agent Anecortave Acetate, in Ocular Tissues of the Posterior Segment. Journal of Ocular Pharmacology and Therapeutics. 26(2). 137–146. 14 indexed citations

11.

Whitson, Jess T., Robert Faulkner, Michael A. Curtis, et al.. (2005). Concentrations of Betaxolol in Ocular Tissues of Patients with Glaucoma and Normal Monkeys after 1 Month of Topical Ocular Administration. Investigative Ophthalmology & Visual Science. 47(1). 235–235. 33 indexed citations

12.

Heacock, Patricia, Elaine Souder, & James E. Chastain. (1996). Subjects, Data, and Videotapes. Nursing Research. 45(6). 336–338. 22 indexed citations

13.

Chastain, James E., F. E. Samson, Sacha B. Nelson, & Thomas L. Pazdernik. (1990). Effects of microdialysis on brain metabolism in normal and seizure states. Neuroscience. 37(1). 155–161. 7 indexed citations

14.

Chastain, James E., et al.. (1989). Kainic acid-induced seizures: Changes in brain extracellular ions as assessed by intracranial microdialysis. Life Sciences. 45(9). 811–817. 6 indexed citations

15.

Chastain, James E., Fred Samson, Stanley R. Nelson, & Thomas L. Pazdernik. (1987). Attenuation of cerebral glucose use in kainic acid-treated rats by diazepam. European Journal of Pharmacology. 142(2). 215–224. 15 indexed citations

16.

Chastain, James E. & Thomas L. Pazdernik. (1985). 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced immunotoxicity. International Journal of Immunopharmacology. 7(6). 849–856. 9 indexed citations

17.

Kaiser, Edwin M., William R. Thomas, James R. McClure, et al.. (1981). Regiointegrity of carbanions derived by selective metalations of dimethylpyridines and -quinolines. Journal of Organometallic Chemistry. 213(2). 405–417. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact